Last Updated on September 27, 2024 by The Health Master
Maharashtra FDA
In a major blow to the ayurvedic medicine industry, the Maharashtra Food and Drugs Administration (Maharashtra FDA) conducted a surprise raid on Gynoveda Femtech Pvt. Ltd., a prominent manufacturer based in Thane.
The raid, which took place resulted in the seizure of ayurvedic medicines valued at a staggering Rs. 6,08,900.
Maharashtra FDA Finds Violations of DMRO Act
The Maharashtra FDA discovered that the seized medicines were in blatant violation of the Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954 (DMROA), and its associated Rules, 1955.
The company’s promotional materials were found to make misleading and exaggerated claims about the efficacy of their products, which is strictly prohibited by the Act.
Investigation Underway
Following the raid, the Maharashtra FDA launched a comprehensive investigation into the company’s manufacturing processes.
The agency is closely examining the quality control measures, labeling practices, and overall compliance with regulatory standards.
Based on the findings of the investigation, the Maharashtra FDA will take appropriate legal action against the individuals and entities responsible for the violations.
Additional Drugs Banned
In addition to the seized medicines, the Maharashtra FDA also prohibited the distribution of other ayurvedic products manufactured by Gynoveda Femtech Pvt. Ltd.
These products were found to have improper labeling and were deemed unfit for sale. The estimated value of the banned drugs is Rs. 3,62,60,900.
Maharashtra FDA Team Leads the Operation
The raid was led by Prashant Brahmankar, the Drugs Inspector of Thane, along with Shashikant Yadav.
The operation was carried out in coordination with senior officials from the Maharashtra FDA, including Commissioner D.R. Gahane, Joint Commissioner Dr. Rahul Khade, and others.
Maharashtra FDA’s Commitment to Public Health
“This action demonstrates our unwavering commitment to safeguarding public health,” stated Commissioner Gahane.”
“We will continue to investigate manufacturers and take necessary steps to ensure that ayurvedic and other traditional medicines are safe and effective.”
The Maharashtra FDA’s crackdown on Gynoveda Femtech Pvt. Ltd. serves as a strong warning to other manufacturers in the industry.
Non-compliance with regulatory requirements can lead to severe consequences, including penalties, sanctions, and restrictions on future business operations.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
CDSCO Updates Guidance for Zonal, Sub-Zonal, and Port Offices
DCC recommends to address drug Brand Name Confusion in India
USFDA Inspection successfully completed at Indian firm Laurus Labs
CDSCO to switch to online submission of Form 44
USFDA inspection finds these lapses at Zydus Lifesciences
Joint raid exposes illegal sale of Tramadol
DCA Telangana seizes huge quantity of Cough Syrup
Key components of Uniform Code for Marketing Practices in Medical Devices (UCMPMD) 2024
NPPA fixed retail price of 62 formulations: September 2024
First USFDA approval granted for Lidocaine Hydrochloride Injection: Aurobindo
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
